Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.

HOPKINTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two presentations at the annual American Association for the Study of Liver Disease (AASLD) conference (The Liver Meeting®) being held in Washington, D.C. on October 20-24, 2017.  The first is an oral presentation entitled: “SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from Cohort 1 of the ACHIEVE trial,” and the second is a late-breaker poster presentation entitled: “Novel anti-viral activity of SB 9200, a RIG-I agonist; results from Cohort 1 of the ACHIEVE trial.”

“SB 9200 is a novel and exciting potential oral therapy with promising antiviral activity, and we are excited to see Professors Yuen and Locarnini, leaders in the field of clinical Hepatology and Virology, present data at this prestigious conference from the first low dose cohort of the ACHIEVE trial showing promising results of SB 9200 in patients with hepatitis B,” said Nezam Afdhal, M.D., D.Sc., Chief Medical Officer, Spring Bank Pharmaceuticals.

The annual AASLD conference will highlight the latest liver diseases research and discuss treatment outcomes with physicians, researchers and healthcare practitioners involved in the science and practice of hepatology. The abstracts will be presented at the conference as follows:

Title: SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from Cohort 1 of the ACHIEVE trial
Author: M.F. Yuen et al
Session:  Parallel Session 5: Hepatitis B New Therapies
Date: October 22, 2017
Time: 10:30 am – 10:45 am
Title: Novel anti-viral activity of SB 9200, a RIG-I agonist; results from Cohort 1 of the ACHIEVE trial 
Author: S. Locarnini et al
Session: Late-Breaking Poster Session
Date: October 23, 2017
Time: 12:30 pm – 2:00 pm

About Spring Bank
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the Company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.

Forward-Looking Statements
Statements in this press release about Spring Bank's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Spring Bank's Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on February 14, 2017, Spring Bank's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which was filed with the SEC on July 31, 2017, and in other filings Spring Bank makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.

For investor inquires:
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993

LifeSci Advisors, LLC
Andrew McDonald
(646) 597-6987

Primary Logo

Source: Spring Bank Pharmaceuticals Inc.